ArticleJournal of gastroenterology2024

Prognostic factors of second-line nivolumab monotherapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study for 184 cases.

Sho Sato et al.PubMed ↗Publisher ↗

No numbers read from the abstract.